Details for New Drug Application (NDA): 202107
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
The generic ingredient in KORLYM is mifepristone. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mifepristone profile page.
Summary for 202107
Tradename: | KORLYM |
Applicant: | Corcept Therap |
Ingredient: | mifepristone |
Patents: | 16 |
Formulation / Manufacturing: | see details |
Pharmacology for NDA: 202107
Mechanism of Action | Progestational Hormone Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for 202107
Suppliers and Packaging for NDA: 202107
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
KORLYM | mifepristone | TABLET;ORAL | 202107 | NDA | Corcept Therapeutics | 76346-073 | 76346-073-01 | 28 TABLET in 1 BOTTLE (76346-073-01) |
KORLYM | mifepristone | TABLET;ORAL | 202107 | NDA | Corcept Therapeutics | 76346-073 | 76346-073-02 | 280 TABLET in 1 BOTTLE (76346-073-02) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
Approval Date: | Feb 17, 2012 | TE: | AB | RLD: | Yes | ||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Aug 12, 2036 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATING CUSHING'S SYNDROME | ||||||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Jan 18, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATING CUSHING'S SYNDROME | ||||||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Apr 20, 2036 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATING CUSHING'S SYNDROME |
Complete Access Available with Subscription